摘要
2021年德国多发性硬化(MS)治疗共识组(MSTCG)发布了最新版的“MSTCG:关于多发性硬化疾病修饰治疗的立场声明(白皮书)”,该白皮书基于最新循证医学证据,对MS的疾病修饰治疗(DMT)形成14条推荐意见,内容涵盖DMT的启动时机、治疗监测、换药策略等,旨在为临床医生提供实践指导,并为治疗决策提供科学基础。白皮书主要参考了欧洲药物获批及临床实践情况,因此在中国的适用性有一定欠缺。但整体来看该指南仍可为中国MS指南的制定提供参考依据,并一定程度上为中国的MS临床实践提供指导意见。文中将对白皮书的部分内容进行介绍和解读。
In 2021,the Multiple Sclerosis Therapy Consensus Group(MSTCG)released the latest version of"Multiple Sclerosis Therapy Consensus Group(MSTCG):position statement on diseasemodifying therapies for multiple sclerosis(white paper)".This white paper was based on the lastest evidence-based medical evidence and provides 14 recommendations on disease-modifying treatment(DMT)for MS.It covers topics including the initiation of DMT,treatment monitoring and switching strategies,aiming to provide practical guidance for clinicians and a scientific basis for treatment decisions.This white paper mainly refers to drug approvals and clinical practices in Europe,resulting in limited applicability in China.However,the guidelines can still provide a reference for the development of guidelines in China and offer guidance for clinical practice to some extent.The some contents of this white paper were introduced and interpreted.
作者
谭红梅
全超
TAN Hong-mei;QUAN Chao(Department of Neurology,Huashan Hospital,Fudan University,Shanghai 200040,China;The National Center for Neurological Disorders,Shanghai 200040,China)
出处
《中国临床神经科学》
2023年第5期547-549,557,共4页
Chinese Journal of Clinical Neurosciences
关键词
多发性硬化
疾病修饰治疗
立场申明
白皮书
multiple sclerosis
disease-modifying therapies
position statement
white paper